POMC and neoplasm: This distinction is primarily based on an ACTH immunohistochemistry and the distribution of secretory granules within tumor cells, but pathologists often employ cytokeratin staining by CAM 5.2, an antibody that targets low-molecular-weight cytokeratins (CK8/18), alongside periodic acid–Schiff (PAS) staining.